Shimadzu Review Vol.78[3・4](2021)
Development of Advanced Core Technology


Practical Solution for Monitoring Antibody Therapeutics in Advanced Immunotherapy

by Takashi Shimada, Ph.D.Noriko Iwamoto, Ph.D.

Shimadzu Review 78[3・4] (2021)


Antibody therapeutics have been mainly used for treating patients with autoimmune diseases, infectious diseases, and cancer. Beginning with rituximab, infliximab, and trastuzumab in the 1990s, monoclonal antibodies have made essential contributions to many treatments. The US Food and Drug Administration has approved more than 100 biologics and nearly 900 of them are currently under development. As one of the technologies for this rapidly expanding area of antibody therapeutics, antibody monitoring of biological samples would play an important role from the development to clinical practice. This can be an indispensable technology for obtaining accurate picture of pharmacokinetics and dose adjustment and/or efficacy assessment by monitoring the level of antibodies in systemic circulation or in disease tissues. We have developed a unique analytical technology for antibody therapeutics that is applicable to a variety of antibodies for treating cancer and autoimmune diseases. In this article, we describe the antibody analysis technology in advanced immunotherapy.

Shimadzu Scientific instruments, Inc., Washington, U.S.A.

*The information contained in Shimadzu Review has not been modified since the original publication date. Please be aware that in some cases, products mentioned within the articles are no longer available.